RVL Pharmaceuticals PLC Investor Relations Material

RVL Pharmaceuticals PLC is a specialty pharmaceutical company that focuses on developing and commercializing products in the ocular and medical aesthetics sectors. Its main product, Upneeq (oxymetazoline hydrochloride ophthalmic solution, 0.1%), is FDA-approved for the treatment of acquired blepharoptosis, or low-lying eyelids, offering a non-surgical option for adults. The company serves underserved patient populations primarily in the United States and operates in several international markets. RVL Pharmaceuticals is headquartered in Bridgewater, New Jersey, and its shares are listed on the OTC Markets.